Bausch Health (BHC) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
29 Oct, 2026Executive summary
14th consecutive quarter of revenue and Adjusted EBITDA growth excluding Bausch + Lomb; quarterly Adjusted EBITDA exceeded $1B for the first time.
Q3 revenue was $2.941B, up 10% reported and 8% organically; Adjusted EBITDA attributable to Bausch Health Companies Inc. rose 32% to $1.305B.
Strong first-nine-month results supported a second consecutive quarterly increase to FY 2026 guidance for revenue, Adjusted EBITDA and adjusted cash flow from operations excluding Bausch + Lomb.
Financial highlights
Q3 operating income was $983M versus $619M; GAAP net income attributable to shareholders was $436M, or $1.15 per diluted share, versus $179M, or $0.48.
Adjusted gross margin was 75%, up 230 bps; adjusted cash flow from operations was $782M, up $274M or 54%.
Consolidated cash provided by operating activities was $813M, up 101%; adjusted net income attributable to shareholders was $673M versus $434M.
Nine-month revenue rose 11% to $8.317B; a $1.426B Salix goodwill impairment contributed to a $729M net loss.
Excluding Bausch + Lomb, Q3 revenue was $1.566B, up 12%; adjusted cash flow from operations was $539M, up $192M.
Outlook and guidance
FY 2026 consolidated revenue guidance increased to $10.975B–$11.175B and Adjusted EBITDA guidance to $4.315B–$4.415B.
FY 2026 guidance excluding Bausch + Lomb: revenue $5.525B–$5.625B, Adjusted EBITDA $3.225B–$3.275B and adjusted cash flow from operations $1.600B–$1.675B.
Guidance excluding Bausch + Lomb implies midpoint growth of 8% for revenue, 13% for Adjusted EBITDA and 29% for adjusted cash flow from operations.
Bausch + Lomb FY 2026 guidance is revenue of $5.450B–$5.550B and Adjusted EBITDA of $1.090B–$1.140B.
Q4 XIFAXAN gross-to-net accruals for the 2027 Medicare price change are expected to reduce revenue growth by 800 bps and Adjusted EBITDA growth by 1,400 bps; inventory normalization may reduce growth by a further 300 and 500 bps, respectively.
Latest events from Bausch Health
- Q2 2026 saw double-digit growth, record margins, raised guidance, and a $1.43B Salix impairment.BHC
Q2 2026 - Sustained growth, robust liquidity, and strategic flexibility underpin future value creation.BHC
Barclays 30th Annual Leveraged Finance Conference 2026 - Sustained growth, China expansion, and BLCO monetization drive strategic priorities.BHC
RBC Capital Markets Global Healthcare Conference 2026 - All director nominees, executive pay, and auditor appointment were approved by majority vote.BHC
AGM 2026 - Double-digit revenue and EBITDA growth, but a $1.43B goodwill impairment drove a net loss.BHC
Q1 2026 - Board recommends approval of all proposals, with strong focus on pay-for-performance and ESG.BHC
Proxy filing - 11th straight quarter of revenue and EBITDA growth, with strong outlook and lower net debt.BHC
Q4 2025 - Q3 revenue up 12%, Adjusted EBITDA up 10%, guidance raised, and net loss narrowed.BHC
Q3 2024 - Q2 2024 revenue up 11% to $2.40B, adjusted EBITDA up 10%, and guidance raised.BHC
Q2 2024